Researchers compared three treatments for obstructive hypertrophic cardiomyopathy across 80 patients, finding that while cardiac myosin inhibitors (CMIs) achieved 93.6% treatment success versus 86.4% for septal myectomy and 72.7% for alcohol septal ablation, the cardiac adaptations differed significantly. CMI therapy showed stable left ventricular strain but subtle early decline in ejection fraction and late deterioration in left atrial function beyond 9-12 months. In contrast, surgical interventions produced progressive improvement in both ventricular and atrial strain over 24 months. This distinction matters because hypertrophic cardiomyopathy affects roughly 1 in 500 adults and can cause sudden cardiac death without proper management. The finding suggests that while newer CMI drugs offer less invasive treatment with high success rates, they may not provide the same long-term cardiac remodeling benefits as established surgical approaches. However, this preprint study awaits peer review and has notable limitations including its single-center design and relatively small cohort sizes, particularly for the ablation group. The results suggest clinicians may need to reconsider surgical options for younger patients requiring decades of management, representing a potentially paradigm-shifting insight for treatment selection.